In recent years, with the widespread use of PD-(L)1 inhibitors, the combination of molecular targeted therapies and PD-(L)1 inhibitors has been recommended as a standard first-line therapy for advanced HCC due to its good effectiveness. Here, CD274 is linked to hepatocellular carcinoma.